Physician profile
Roopa Roy
NPI 1437449642
$2,002.77
in general payments reported to CMS, 2019-2025
12 companies · $667 in 2025
The $667 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $116 · 2020: $40.59 · 2022: $111 · 2023: $371 · 2024: $697 · 2025: $667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,735.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,735.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $775.01 | 2019-2025 | Freestyle Libre 3 |
| Beta Bionics, INC. | $296.54 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Corcept Therapeutics | $228.24 | 2022-2024 | Korlym |
| Dexcom, INC. | $195.22 | 2023-2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $187.86 | 2024-2025 | Minimed 780g |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.91 | 2024 | Jardiance |
| Intuity Medical INC | $69.24 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Medtronic Minimed, INC. | $56.53 | 2019-2020 | |
| Tandem Diabetes Care, INC. | $44.74 | 2019-2020 | |
| Amphastar Pharmaceuticals, INC. | $16.94 | 2023 | Baqsimi |
| Novo Nordisk INC | $14.75 | 2019 | |
| Lilly USA, LLC | $12.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roopa Roy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.